FDA approves RYBREVANT and LAZCLUZE for EGFR-mutated advanced lung cancer

The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced ... Read More